<DOC>
	<DOCNO>NCT01489566</DOCNO>
	<brief_summary>This randomize , double-blinded , placebo-controlled , multi-center Clinical Trial . Patients tumor lesion one month resection hepatocellular carcinoma randomize 1:1 ratio 1 2 treatment groups：6mg/d Tyroserleutide ( injection ) , placebo . The objective evaluate effect Injectable Tyroserleutide recurrence-free survival , overall survival , quality life , safety tolerability subject resection hepatocellular carcinoma</brief_summary>
	<brief_title>Study Tyroserleutide Injection Hepatocellular Carcinoma ( HCC ) Patients</brief_title>
	<detailed_description>- Subjects return hospital 25±5 day resection hepatocellular carcinoma follow baseline examination . Baseline image data send lead study site image center review verification . The investigator determine whether subject satisfies inclusion/exclusion criterion . If requirement satisfy , randomization occur 25±5 day surgery - The day randomization define Day 0 . Randomized subject return hospital begin cycle 1 day randomization ( Day 0 ) . The Investigator administer chemotherapy accord subject 's condition . On next day , experimental drug therapy begin , relevant laboratory test perform within 3 day end study drug infusion . - Cycles occur every four week first 6 cycle ( i.e . cycle 2 , 3 , 4 , 5 , 6 begin day 28 ± 3 , 56 ± 3 , 84 ± 3 , 112 ± 3 , 140 ± 3 , respectively ) . The second 6 cycle occur every eight week ( i.e . cycle 7 , 8 , 9 , 10 , 11 , begin day 196 ± 3 , 252 ± 3 , 308 ± 3 , 364 ± 3 , 420 ± 3 , respectively ) . - participant receive medical inspection observe ensure drug safety . - A CT scan perform participant exclude recurrence metastasis tumor assess effect treatment initiation new cycle .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>Perioperative Period Inclusion Criteria 1 . Signed informed consent ; 2 . Aged ≥ 18 year ≤ 75 year old , male female； 3 . Subject underwent complete resection hepatocellular carcinoma ( confirmed pathology ) ; 4 . The tumor characteristic must meet one follow : Tumor thrombosis portal vein branch detect either ; Preoperative imaging , ; Intraoperative visual observation . Tumor thrombosis portal vein branch detect ; A single tumor maximum diameter ≥8cm confirm preoperative imaging , histological evidence micro vascular tumor thrombosis ; Preoperative imaging confirm 2 tumor lesion Perioperative Period Exclusion Criteria 1 . Concomitant malignant primary tumor ( ) system is/are present ; 2 . Tumor thrombosis main branch portal vein hepatic vein detect preoperative imaging observe surgery ; 3 . The subject receive previous systemic antiHCC therapy prior resection surgery ( except resection surgery ) , liver transplantation , intervention , ablation , radiotherapy , chemotherapy , molecular target therapy antiHCC therapy ; 4 . The subject take study/investigational drug 7 day prior resection surgery ; 5 . The subject central nervous system disease , mental illness , unstable angina , congestive heart failure , severe arrhythmia severe uncontrolled disease ; 6 . The subject history study drug similar drug allergy Baseline ( PostSurgeryDay 25 ± 5 ) Inclusion Criteria 1 . Baseline ( postresection ) liver CT ( normal CT + contrast enhance CT ) chest CT scan show tumor lesion ; 2 . ChildPugh score class A baseline Baseline ( PostSurgeryDay 25 ± 5 ) Exclusion Criteria 1 . Body surface area &lt; 1.47 m2 &gt; 1.92 m2 ; 2 . Concomitant malignant primary tumor ( ) system is/are present ; 3 . The subject take study/investigational drug within 4 week prior randomization ; 4 . The baseline examination indicate infection , bleeding , bile leakage , postoperative complication present ; 5 . The baseline examination suggest presence tumor metastasis ; 6 . The subject central nervous system disease , mental illness , unstable angina , congestive heart failure , severe arrhythmia severe uncontrolled disease ; 7 . The subject history investigational drug similar drug allergy ; 8 . The subject pregnant , lactating , urine pregnancy test result positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hepatocellular , Carcinoma , recurrence</keyword>
</DOC>